Overview

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small cell lung cancer (NSCLC), this prospective, single-arm Phase II clinical trial with safety lead-in will test the feasibility and outcomes of this approach.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Durvalumab
Paclitaxel